keyword
MENU ▼
Read by QxMD icon Read
search

Rosuvastatin

keyword
https://www.readbyqxmd.com/read/28441890/rosuvastatin-ameliorates-cognitive-impairment-in-rats-fed-with-high-salt-and-cholesterol-diet-via-inhibiting-acetylcholinesterase-activity-and-amyloid-beta-peptide-aggregation
#1
I Husain, M Akhtar, M Zainul Abdin, M Islamuddin, M Shaharyar, A K Najmi
Amyloid beta (Aβ) peptide aggregation and cholinergic neurodegeneration are involved in the development of cognitive impairment. Therefore, in this article, we examined rosuvastatin (RSV), an oral hypolipidemic drug, to determine its potential as a dual inhibitor of acetylcholinesterase (AChE) and Aβ peptide aggregation for the treatment of cognitive impairment. Molecular docking study was done to examine the affinity of RSV with Aβ1-42 and AChE in silico. We also employed neurobehavioral activity tests, biochemical estimation, and histopathology to study the anti-Aβ1-42 aggregation capability of RSV in vivo...
January 1, 2017: Human & Experimental Toxicology
https://www.readbyqxmd.com/read/28437620/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-guidelines-for-management-of-dyslipidemia-and-prevention-of-cardiovascular-disease
#2
Paul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, George Grunberger, Chris K Guerin, David S H Bell, Jeffrey I Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A Brinton, Sergio Fazio, Michael Davidson
OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). METHODS: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols...
April 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28429691/comparison-of-the-effects-of-high-dose-atorvastatin-and-high-dose-rosuvastatin-on-oxidative-stress-in-patients-with-acute-myocardial-infarction-a-pilot-study
#3
Celal Kilit, Fatma Emel Koçak, Türkan Paşalı Kilit
OBJECTIVE: Oxidative stress is increased in patients with acute myocardial infarction (AMI). Statins reduce oxidative stress independent of their effect in reducing low-density lipoprotein cholesterol (LDL-C). The aim of the present study was to compare the effects of atorvastatin and rosuvastatin on oxidative status by investigating serum paraoxonase, serum arylesterase, total oxidant status, total antioxidant status (TAS) and oxidative stress index (OSI) in patients with AMI. METHODS: Seventy patients with AMI were randomized into 2 groups; total of 55 patients (19 females, 36 males) aged 32 to 86 years completed the study and were included in the analysis...
April 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28428922/the-cost-benefit-balance-of-statins-in-hawai-i-a-moving-target
#4
Corey J Lum, Kazuma Nakagawa, Ralph V Shohet, Todd B Seto, Deborah A Taira
Statins are lipid-lowering medications used for primary and secondary prevention of atherosclerotic disease and represent a substantial portion of drug costs in the United States. A better understanding of prescribing patterns and drug costs should lead to more rational utilization and help constrain health care expenditures in the United States. The 2013 Medicare Provider Utilization and Payment Data: Part D Prescriber Public Use File for the State of Hawai'i was analyzed. The number of prescriptions for statins, total annual cost, and daily cost were calculated by prescriber specialty and drug...
April 2017: Hawai'i Journal of Medicine & Public Health: a Journal of Asia Pacific Medicine & Public Health
https://www.readbyqxmd.com/read/28425285/directed-evolution-of-carbonyl-reductase-from-rhodosporidium-toruloides-and-its-application-in-stereoselective-synthesis-of-tert-butyl-3r-5s-6-chloro-3-5-dihydroxyhexanoate
#5
Zhi-Qiang Liu, Lin Wu, Xiao-Jian Zhang, Ya-Ping Xue, Yu-Guo Zheng
tert-Butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate ((3R,5S)-CDHH) is a key intermediate of atorvastatin and rosuvastatin synthesis. Carbonyl reductase RtSCR9 from Rhodosporidium toruloides exhibited excellent activity toward tert-butyl (S)-6-chloro-3-hydoxy-5-oxohexanoate ((S)-CHOH). To improve the activity of RtSCR9, random mutagenesis and site-saturation mutagenesis were performed. Three positive mutants were obtained (mut-Gln95Asp, mut-Ile144Lys and mut-Phe156Gln). These mutants exhibited 1.94-, 3.03- and 1...
April 20, 2017: Journal of Agricultural and Food Chemistry
https://www.readbyqxmd.com/read/28423147/adherence-to-high-intensity-statins-following-a-myocardial-infarction-hospitalization-among-medicare-beneficiaries
#6
Lisandro D Colantonio, Lei Huang, Keri L Monda, Vera Bittner, Maria-Corina Serban, Benjamin Taylor, Todd M Brown, Stephen P Glasser, Paul Muntner, Robert S Rosenson
Importance: High-intensity statins are recommended following myocardial infarction. However, patients may not continue taking this medication with high adherence. Objective: To estimate the proportion of patients filling high-intensity statin prescriptions following myocardial infarction who continue taking this medication with high adherence and to analyze factors associated with continuing a high-intensity statin with high adherence after myocardial infarction...
April 19, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28422300/platelet-reactivity-in-response-to-loading-dose-of-atorvastatin-or-rosuvastatin-in-patients-with-stable-coronary-disease-before-percutaneous-coronary-intervention-the-statiplat-randomized-study
#7
Cosmo Godino, Anna Giulia Pavon, Antonio Mangieri, Anna Salerno, Michela Cera, Alberto Monello, Alaide Chieffo, Valeria Magni, Alberto Cappelletti, Alberto Margonato, Antonio Colombo
BACKGROUND: The acute effects of statin loading dose (LD) on platelet reactivity in patients with chronic stable angina (CSA) are not completely clear. HYPOTHESIS: We hypothesized that LDs of atorvastatin and rosuvastatin have different pharmacodynamic acute effects on platelet aggregability in CSA patients with baseline normal platelet reactivity while on dual antiplatelet therapy (DAPT). METHODS: From September 2011 to February 2014, all consecutive CSA patients on chronic DAPT (aspirin and clopidogrel) were evaluated before elective percutaneous coronary intervention (PCI)...
April 19, 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/28417263/rosuvastatin-attenuates-high-salt-and-cholesterol-diet-induced-neuroinflammation-and-cognitive-impairment-via-preventing-nuclear-factor-kappab-pathway
#8
Ibraheem Husain, Mohd Akhtar, Divya Vohora, Malik Zainul Abdin, Mohammad Islamuddin, Mohd Jawaid Akhtar, Abul Kalam Najmi
Recent attention is focused on the impact of diet on health and mental well-being. High-salt and cholesterol diet (HSCD) is known to be associated with neuroinflammation which is the predominant factor for neurodegenerative disease like Alzheimer disease (AD). In the present study, we examined the neuroprotective potential of rosuvastatin, an HMG-CoA reductase inhibitor against HSCD induced neuroinflammation and cognitive impairment. Our results demonstrated that HSCD-induced cognitive impairment as determined by Morris water maze (MWM) task...
April 18, 2017: Neurochemical Research
https://www.readbyqxmd.com/read/28416099/statin-use-and-risk-of-new-onset-diabetes-a-meta-analysis-of-observational-studies
#9
M Casula, F Mozzanica, L Scotti, E Tragni, A Pirillo, G Corrao, A L Catapano
BACKGROUND AND AIMS: Meta-analyses of randomized control trials investigating the association between incident diabetes and statin use showed an increased risk of new-onset diabetes (NOD) from 9% to 13% associated with statins. However, short follow-up period, unpowered sample size, and lack of pre-specified diagnostic criteria for diabetes detection could be responsible of an underestimation of this risk. We conducted a meta-analysis of published observational studies to evaluate the association between statins use and risk of NOD...
March 10, 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/28410843/left-ventricular-hypertrophy-does-not-prevent-heart-failure-in-experimental-hypertension
#10
H Hernán Gómez Llambí, G Cao, M Donato, D Suárez, G Ottaviano, A Müller, B Buchholz, R Gelpi, M Otero-Losada, J Milei
BACKGROUND: Left ventricular hypertrophy (LVH) secondary to hypertension has been accepted to prevent heart failure (HF) while paradoxically increasing cardiovascular morbi-mortality. OBJECTIVES: To evaluate whether antihypertensive treatment inhibits LVH, restores beta-adrenergic response and affects myocardial oxidative metabolism. METHODS: Ninety spontaneously hypertensive rats (SHR) were distributed into groups and treated (mg/kg, p.o...
March 27, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28406125/effect-of-rosuvastatin-on-dyslipidemia-and-other-parameters-associated-with-metabolic-syndrome-in-saudi-patients
#11
M M Rafeeq, H S Habib, Has Murad, M A Gari, Z J Gazzaz
CONTEXT: Metabolic syndrome (MS) is a constellation of metabolic irregularities consisting of dyslipidemia, hypertension, hyperglycemia, chronic inflammatory, and hypercoagulable state predisposing to diabetes and cardiovascular events. Statins are first-line drugs to treat the associated atherogenic dyslipidemia. AIM: Effect of rosuvastatin on MS in Saudi patients was studied. SETTINGS AND DESIGN: Prospective, open label, randomized clinical study...
April 2017: Nigerian Journal of Clinical Practice
https://www.readbyqxmd.com/read/28398205/drug-eruption-caused-by-rosuvastatin
#12
T Oda, Y Sawada, T Yamaguchi, S Ohmori, S Haruyama, M Yoshioka, E Okada, M Nakamura
No abstract text is available yet for this article.
2017: Journal of Investigational Allergology & Clinical Immunology
https://www.readbyqxmd.com/read/28395888/relation-of-intensity-of-statin-therapy-and-outcomes-after-transcatheter-aortic-valve-replacement
#13
Chetan P Huded, Lillian R Benck, Neil J Stone, Ranya N Sweis, Mark J Ricciardi, S Chris Malaisrie, Charles J Davidson, James D Flaherty
Statin therapy is associated with improved survival in patients at high risk for cardiovascular mortality, but the impact of statin therapy in patients treated with transcatheter aortic valve replacement (TAVR) is unknown. We reviewed 294 consecutive cases of TAVR performed at a single tertiary care medical center. We defined high-intensity statin therapy as atorvastatin 40 to 80 mg/day or rosuvastatin 20 to 40 mg/day. Study outcomes included post-TAVR adverse events, 30-day mortality, and overall survival...
March 16, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28394933/the-acute-impact-of-high-dose-lipid-lowering-treatment-on-endothelial-progenitor-cells-in-patients-with-coronary-artery-disease-the-remedy-epc-early-substudy
#14
Rosalinda Madonna, Francesca Vera Renna, Paola Lanuti, Matteo Perfetti, Marco Marchisio, Carlo Briguori, Gerolama Condorelli, Lamberto Manzoli, Raffaele De Caterina
RATIONALE AND OBJECTIVE: Endothelial progenitor cells (EPCs) play a role in vascular repair, while circulating endothelial cells (CECs) are biomarkers of vascular damage and regeneration. Statins may promote EPC/CEC mobilization in the peripheral blood. We evaluated whether pre-procedural exposure to different lipid-lowering drugs (statins±ezetimibe) can acutely increase levels/activity of EPCs/CECs in patients with stable coronary artery disease (CAD). METHODS: In a planned sub-analysis of the Rosuvastatin For REduction Of Myocardial DamagE During Coronary AngioplastY (REMEDY) trial, 38 patients with stable CAD on chronic low-dose statin therapy were randomized, in a double-blind, placebo-controlled design, into 4 groups before PCI: i...
2017: PloS One
https://www.readbyqxmd.com/read/28394011/how-has-the-treatment-of-hypercholesterolemia-in-poland-changed-over-the-last-6-years
#15
Agnieszka Kapłon-Cieślicka, Marcin Michalak, Łukasz Kołtowski, Krzysztof J Filipiak
BACKGROUND: To assess changes in the treatment of hypercholesterolemia in Polish ambulatory care over the last 6 years. METHODS: Data were obtained from two separate questionnaire-based studies, conducted in 2009 and 2015. The analysis included only those patient visits, which were associated with modifications of previous hypercholesterolemia treatment (1924 visits from the year 2009 and 1888 visits from the year 2015). RESULTS: In the present registry, there was a 19 mg/dL reduction in the level of total cholesterol and a 17 mg/dL reduction in the level of low-density lipoprotein compared to year 2009...
April 10, 2017: Cardiology Journal
https://www.readbyqxmd.com/read/28392500/metabolism-and-proteomics-of-large-and-small-dense-ldl-in-combined-hyperlipidemia-effects-of-rosuvastatin
#16
Nuntakorn Thongtang, Margaret R Diffenderfer, Esther M M Ooi, P Hugh R Barrett, Scott M Turner, Ngoc-Anh Le, W Virgil Brown, Ernst J Schaefer
Small dense LDL (sdLDL) has been reported to be more atherogenic than large buoyant LDL (lbLDL). We examined the metabolism and protein composition of sdLDL and lbLDL in six subjects with combined hyperlipidemia on placebo and rosuvastatin 40 mg/day. ApoB-100 kinetics in triglyceride rich lipoproteins (TRL), lbLDL (density [d] 1.019-1.044 g/ml), and sdLDL (d 1.044-1.063 g/ml) were determined in the fed state using stable isotope tracers, mass spectrometry, and compartmental modeling. Compared with placebo, rosuvastatin decreased LDL cholesterol and apoB-100 levels in TRL, lbLDL, and sdLDL by significantly increasing the fractional catabolic rate of apoB-100 (TRL +45%; lbLDL +131%; sdLDL +97%), without a change in production...
April 9, 2017: Journal of Lipid Research
https://www.readbyqxmd.com/read/28391887/investigating-the-prevalence-predictors-and-prognosis-of-suboptimal-statin-use-early-after-a-non-st-elevation-acute-coronary-syndrome
#17
Richard M Turner, Peng Yin, Anita Hanson, Richard FitzGerald, Andrew P Morris, Rod H Stables, Andrea L Jorgensen, Munir Pirmohamed
BACKGROUND: High-potency statin therapy is recommended in the secondary prevention of cardiovascular disease but discontinuation, dose reduction, statin switching, and/or nonadherence occur in practice. OBJECTIVES: To determine the prevalence and predictors of deviation from high-potency statin use early after a non-ST elevation acute coronary syndrome (NSTE-ACS) and its association with subsequent major adverse cardiovascular events (MACE) and all-cause mortality (ACM)...
January 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28385543/rosuvastatin-pharmacokinetics-in-asian-and-white-subjects-wild-type-for-both-oatp1b1-and-bcrp-under-control-and-inhibited-conditions
#18
Hsin-Fang Wu, Nadya Hristeva, Jae Chang, Xiaorong Liang, Ruina Li, Lynda Frassetto, Leslie Z Benet
The FDA recommends rosuvastatin dosage reductions in Asian patients because pharmacokinetic studies have demonstrated an approximate two-fold increase in median exposure to rosuvastatin in Asian subjects when compared to Caucasian controls. Yet, no explanation for this ethnic difference has been confirmed. Here we show that rosuvastatin exposure in Asians and Whites does not differ significantly when all subjects are wildtype carriers for both Solute Carrier Organic anion transporter1B1 *1a and ATP Binding Cassette Subfamily G Member 2 c...
April 3, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28374849/efficacy-of-alirocumab-according-to-background-statin-type-and-dose-pooled-analysis-of-8-odyssey-phase-3-clinical-trials
#19
Alberico L Catapano, L Veronica Lee, Michael J Louie, Desmond Thompson, Jean Bergeron, Michel Krempf
Low-density lipoprotein cholesterol (LDL-C) reductions with the PCSK9 monoclonal antibody alirocumab may be affected by background statin dose due to increased PCSK9 levels with higher statin doses. Data from 8 Phase 3 trials conducted with background statin (n = 4629) were pooled by alirocumab dose (75 or 150 mg every 2 weeks) and control (placebo/ezetimibe), and analyzed by background statin type/dose. Overall, 58.4% received high-dose statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg, simvastatin 80 mg), 28...
April 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28359413/limited-added-value-of-circulating%C3%A2-inflammatory-biomarkers-in%C3%A2-chronic-heart%C3%A2-failure
#20
Ståle H Nymo, Pål Aukrust, John Kjekshus, John J V McMurray, John G F Cleland, John Wikstrand, Pieter Muntendam, Ursula Wienhues-Thelen, Roberto Latini, Erik Tandberg Askevold, Jørgen Gravning, Christen P Dahl, Kaspar Broch, Arne Yndestad, Lars Gullestad, Thor Ueland
OBJECTIVES: This study sought to evaluate whether a panel of biomarkers improved prognostication in patients with heart failure (HF) and reduced ejection fraction of ischemic origin using a systematized approach according to suggested requirements for validation of new biomarkers. BACKGROUND: Modeling combinations of multiple circulating markers could potentially identify patients with HF at particularly high risk and aid in the selection of individualized therapy...
April 2017: JACC. Heart Failure
keyword
keyword
6832
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"